Regress subklinicheskogo porazheniya organov-misheney u bol'nykh gipertonicheskoy bolezn'yu na fone razlichnykh podkhodov k naznacheniyu kombinirovannoy antigipertenzivnoy terapii


如何引用文章

全文:

详细

参考

  1. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007; 25: 1105-87.
  2. Coutinho T, Turner ST, Kullo I. Aortic pulse wave velocity is associated with measures of subclinical target organ damage. JACC Cardiovasc Imaging 2011; 4 (7): 754-61.
  3. García-García A, Gómez-Marcos MA, Recio-Rodriguez JI et al. Relationship between ambulatory arterial stiffness index and subclinical target organ damage in hypertensive patients. J Hypertens Res 2011; 34 (2): 180-6.
  4. Matsumoto C, Tomiyama H, Yamada J. Brachial-ankle pulse wave velocity as a marker of subclinical organ damage in middle-aged patients with hypertension. J Cardiol 2008; 51 (3): 163-70.
  5. Triantafyllidi H, Tzortzis S, Lekakis J et al. Association of target organ damage with three arterial stiffness indexes according to blood pressure dipping status in untreated hypertensive patients. Am J Hypertens 2010; 23 (12): 1265-72.
  6. Castro MM, Tanus-Santos JE, Gerlach RF Matrix metalloproteinases: Targets for doxycycline to prevent the vascular alterations of hypertension. Pharmacol Res 2011; 64 (6): 567-72.
  7. Jones CB, Sane DC, Herrington DM Matrix metalloproneinases. The review of their structure and role in acute coronary syndromes. Cardiovasc Res 2003; 59 (4): 812-23.
  8. Fontana V, Silva PS, Belo VA et al. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target. Basic Clin Pharmacol Toxicol 2011; 109 (2): 130-7.
  9. Kurdi M, Booz GW. New take on the role of angiotensin II in cardiac hypertrophy and fibrosis. Hypertension 2011; 57 (6): 1034-8.
  10. Collier P, Watson CJ, Voon V et al. Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail 2011; 13 (10): 1087-95.
  11. de la Sierra A. Prevention of progression and regression of target organ damage. Future strategies Rev Clin Esp 2011; 211 (Suppl. 1): 8-14.
  12. Smith DH. Fixed-dose combination antihypertensives and reduction in target organ damage: are they all the same? Am J Cardiovasc Drugs 2007; 7 (6): 413-22.
  13. Schroeder K, Fahey T, Hay AD et al. Relationship between medication adherence and blood pressure in primary care: prospective study. J Hum Hypertens 2006; 20 (8): 625-7.
  14. Menne J, Chatzikyrkou C, Haller H. Microalbuminuria as a risk factor: the influence of renin-angiotensin system blockade. J Hypertens 2010; 28 (10): 198-94.
  15. Blacklock CL, Hirst JA, Taylor KS et al. Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis. Diabet Med 2011; 28 (10): 1182-7.
  16. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372 (9638): 547-53.
  17. Mallareddy M, Parikh CR, Peixoto AJ. Effect of angiotensin-converting enzyme inhibitors on arterial stiffness in hypertension: systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2006; 8(6): 398-403.
  18. Vyssoulis GP, Karpanou EA, Kyvelou SM et al. Beneficial effect of angiotensin II type 1 receptor blocker antihypertensive treatment on arterial stiffness: the role of smoking. J Clin Hypertens (Greenwich) 2008; 10 (3): 201-7.
  19. Sonoda M, Aoyagi T, Takenaka K et al. A one-year study of the antiatherosclerotic effect of the angiotensin-II receptor blocker losartan in hypertensive patients. A comparison with angiotension-converting enzyme inhibitors. Int Heart J 2008; 49 (1): 95-103.
  20. Ali K, Rajkumar C, Fantin F et al. Irbesartan improves arterial compliance more than lisinopril. Vasc Health Risk Manag 2009; 5 (4): 587-92.
  21. Castro MM, Rizzi E, Prado CM et al. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling. Matrix Biol 2010; 29 (3): 194-201.
  22. Lim CS, Shalhoub J, Gohel MS et al. Matrix metalloproteinases in vascular disease - a potential therapeutic target? Curr Vasc Pharmacol 2010; 8 (1): 75-85.
  23. Hayashi K, Sasamura H, Ishiguro K et al. Regression of glomerulosclerosis in response to transient treatment with angiotensin II blockers is attenuated by blockade of matrix metalloproteinase-2. Kidney Int 2010; 78 (1): 69-78.
  24. Ishiguro K, Hayashi K, Sasamura H et al. «Pulse» treatment with high-dose angiotensin blocker reverses renal arteriolar hypertrophy and regresses hypertension. Hypertension 2009; 53 (1): 83-9.
  25. Tayebjee MH, Nadar S, Blann AD et al. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens 2004; 17 (9): 764-9.
  26. Yamamoto D, Takai S. Pharmacological implications of MMP-9 inhibition by ACE inhibitors. Curr Med Chem 2009; 16 (11): 1349-54.
  27. Cheng XW, Song H, Sasaki T et al. Angiotensin type 1 receptor blocker reduces intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Hypertension 2011; 57 (5): 981-9.
  28. Maejima Y, Okada H, Haraguchi G et al. Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma. Lab Invest 2011; 91 (6): 932-44.
  29. Onal IK, Altun B, Onal ED, et al. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. Eur J Intern Me 2009; 20 (4): 369-72.
  30. Waeber B, Feihl F, Ruilope LM Fixed-dose combinations as initial therapy for hypertension: a review of approved agents and a guide to patient selection. Drugs 2009; 69 (13): 1761-76.
  31. Martin DE, DeCherney GS, Ilson BE et al. Eprosartan, an angiotensin II receptor antagonist, does not affect the pharmacodynamics of glyburide in patients with type II diabetes mellitus. J Clin Pharmacol 1997; 37 (2): 155-9.
  32. Ilson BE, Boike SC, Martin DE et al. A dose-response study to assess the renal hemodynamic, vascular, and hormonal effects of eprosartan, an angiotensin II AT1-receptor antagonist, in sodium-replete healthy men. Clin Pharmacol Ther 1998; 63 (4): 471-81.

补充文件

附件文件
动作
1. JATS XML
下载


Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 83918 от 12.09.2022 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 83917 от 12.09.2022 г.


##common.cookie##